May 13th 2025
The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Implementation of ICH Q3D Elemental Impurities Guideline: Challenges and Opportunities
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.